Search
Halozyme Therapeutics Inc
HALOAdd to Watchlist
72.635USD
+1.485+2.09%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
8.56BMarket Cap
24.57P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.09%
5 Days
+5.93%
1 Month
+6.32%
6 Months
+6.18%
Year to Date
+7.93%
1 Year
+34.76%
Key Figures
71.380Open
73.530High
1.46MVolume
24.57P/E TTM
7.45P/E Dynamic
--Dividend TTM
1.24%Turnover Ratio
71.150Prev. Close
71.380Low
82.02MTurnover
19.26P/E Static
175.26P/B
0.00%Div Yield TTM
14.33%ROA
82.22052wk High
0.67Volume Ratio
444.09MNet Profit
117.78MShares
2.9559EPS TTM
0.88Beta
99.40%ROE
51.06052wk Low
3.02%Amplitude
71.13%Gross Margin
8.56BMarket Cap
2.12Reward/Risk
1.72%Risk Rate
TradingKey Stock Score of Halozyme Therapeutics Inc
Currency: USD Updated: 2026-06-24Key Insights
Halozyme Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 21 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 85.44.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Halozyme Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Halozyme Therapeutics Inc Highlights
StrengthsRisks
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 68.42% year-on-year.
Overvalued
The company’s latest PE is 24.07, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 138.78M shares, increasing 3.55% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 49.38K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
85.444
Target Price
+22.73%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Halozyme Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Halozyme Therapeutics Inc Info
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Ticker SymbolHALO
CompanyHalozyme Therapeutics Inc
CEOTorley (Helen I)
Websitehttps://www.halozyme.com/
Related Instruments
+1.16%
+1.66%
+1.48%
+3.67%
+4.05%
+1.27%
+0.40%
+0.44%
-1.05%
-1.48%
+1.05%
+0.75%
+1.55%
+1.14%
-0.20%
0.00%
-0.53%
+0.73%
+4.24%
-0.54%Popular Instruments
52024.700
+53.000 (+0.10%)
29455.000
-339.200 (-1.14%)
7366.800
-43.600 (-0.59%)
15751.000
+214.000 (+1.38%)
71132.000
+175.000 (+0.25%)
6265.800
+37.600 (+0.60%)
71.344
+1.585 (+2.27%)
275.150
-17.930 (-6.12%)
195.740
-3.260 (-1.64%)
4026.150
+27.410 (+0.69%)
FAQs
What is the current price of Halozyme Therapeutics Inc (HALO)?
The current price of Halozyme Therapeutics Inc (HALO) is 71.15.
What is the symbol of Halozyme Therapeutics Inc?
The ticker symbol of Halozyme Therapeutics Inc is HALO.
What is the 52-week high of Halozyme Therapeutics Inc?
The 52-week high of Halozyme Therapeutics Inc is 82.22.
What is the 52-week low of Halozyme Therapeutics Inc?
The 52-week low of Halozyme Therapeutics Inc is 51.06.
What is the market capitalization of Halozyme Therapeutics Inc?
The market capitalization of Halozyme Therapeutics Inc is 8.44B.
Is Halozyme Therapeutics Inc (HALO) currently rated as Buy, Hold, or Sell?
According to analysts, Halozyme Therapeutics Inc (HALO) has an overall rating of Buy, with a price target of 85.44.
What is the Earnings Per Share (EPS TTM) of Halozyme Therapeutics Inc (HALO)?
The Earnings Per Share (EPS TTM) of Halozyme Therapeutics Inc (HALO) is 2.64.
